Skip to content

The study on the correlation between LOH-BPH and polymorphisms of sex hormone-related genes and their metabolism

The study on the correlation between LOH-BPH and polymorphisms of sex hormone-related genes and their metabolism

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400091704
Enrollment
Unknown
Registered
2024-11-01
Start date
2022-12-31
Completion date
Unknown
Last updated
2024-11-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

prostate disease

Interventions

LOH-BPH group:none
non-LOH-BPH group:none

Sponsors

Affiliated Hospital of Zunyi Medical University
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
52 Years to 86 Years

Inclusion criteria

Inclusion criteria: 1.(i) middle-aged and elderly men in the community; 2.(ii) completes the IPSS score and AMS questionnaire; 3.(iii) participated in routine physical examination and the prostate examination; 4.(iv) completed the detection of sex hormones and single nucleotide polymorphisms of genes related to sex hormone metabolism; 5.(v) completed the blood PSA detection and routine biochemical index detection.

Exclusion criteria

Exclusion criteria: 1.(i) when a PSA greater than 4ng/ml were encountered, a prostate biopsy was required provided that the criteria for prostate biopsy were met, and the diagnosis of prostate cancer was excluded before participants could be recruited into this study; 2.(ii) to minimize latent confounding factors and bias, the participants who had a history of prostate or urethral surgery, those who had been diagnosed with urologic diseases, including prostatitis, epididymitis, orchitis, testicular tumor, testicular tuberculosis, testicular trauma, testicular absence, cryptorchidism, urethral stricture, urologic infections, malignancy, or neurogenic bladder; 3.(iii) and those who had been taking medicine, including anticholinergics, 5a-reductase inhibitors, phosphodiesterase-5 inhibitors, and hormone replacement therapy were excluded from the study.

Design outcomes

Primary

MeasureTime frame
single nucleotide polymorphisms;

Secondary

MeasureTime frame
Age;Total testosterone;Sex hormone binding globulin;Insulin;Smoking status;Quality of life score;Body mass index;waist circumference;Systolic pressure;Diastolic blood pressure;Blood glucose;Triglyceride;High-density lipoprotein cholesterol;Low density lipoprotein cholesterol;Total cholesterol;Total prostate volume;International Prostate Symptom Scale;Voiding symptom;Prostate specific antigen;Maximum urinary flow rate;Estradiol;Dihydrotestosterone;International Index of Erectile Function-5;Drinking condition;

Countries

China

Contacts

Public ContactZongping Chen; Congcong Chen

Affiliated Hospital of Zunyi Medical University

2404259310@qq.com+86 13508512561

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026